Dena Westphalen

Articles by Dena Westphalen

81 A First-in-Human Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients Who Have Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

ByDena Westphalen,Sarah Goldberg, MD, MPH ,Muhammad Rizwan Khawaja, MD, MPH,Jose Pacheco, MD,Jeffrey Russell,Joshua K. Sabari, MD,Jenna Zhang,Meredith Little,Kevin Moynihan,Kathleen Dorris,Mohamad Adham Salkeni

June 7th 2026

A phase 1/1b first-in-human study is evaluating the CNS-penetrant selective ERBB2 inhibitor CGT4255 across multiple tumor types, including HER2-positive breast cancer with brain metastases.

Latest Updated Articles

Dena Westphalen

Articles by Dena Westphalen

81 A First-in-Human Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients Who Have Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

Latest Updated Articles

Trending on CancerNetwork

What Separates a Next-Generation Liver Tumor Board From the Traditional Model?

Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant

BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC

MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance

Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML